Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The Actual Benefit of XEROQUEL LP in the treatment of schizophrenia is substantial. |
Clinical Added Value
| no clinical added value |
XEROQUEL LP does not provide an Improvement in Actual Benefit (IAB level V) compared with other treatments available in this indication. |
eNq1mE1z2jAQhu/8Co8PvWFjQiBubTItTVpmkiklMO30wgh7CaJGcvQBpL++MoaGdOSmEehoy353pV09ekfR5WaZOStgHFMSu4HXcB0gCU0xuY/d8ei6fuFedmvRAq3QwWcdr+EFTddJMsR57Baj3hQQ4d7325uPoP4H5nZrTkSnC0jEs++kwJn3GfH5LcqLb5xoRXHqLEHMaRq7uRTbt07EBVNZdNeU/eQ5SiDyd28ORxeT1uH7yC/E/kNVcmA3iNxrRYEYaSaSMSCihwTcU/ZYke+ZkTbmQ+BUsgQGSMwHjK5wCqk2xAxlHIyCzNbpHbBVBqIIohX3F8mSG4mjBdoM4aGvT/q9Gu2Jjag36kGnE4aNdtBsh63QKBQ7WCp9FdQk/GQSNFtBO+z4QPwNMPogITMszoAygTJLZcG897yzLMVh8PBi+VPM8ww9eguemy4VYkgNA1P7395EihmMmCJSptbsL30is8x/ZdbjHS8sZVzgqEclERXYuB6aLkSPEgGb6oqakU5sdr2IgZ9O9hclesoP5DTDiSnTFHUkcDEe9quRdlIafEAcxsweDr5hktI1Pz1mDstqKft8S0qtaM7SYNIML9rB+bnxLvqheqjijLmSjObgKwBhfgxX+mRGjyWKaku91L4pT9ePW6tDE5RBhdmpG9JFNeLem1lrdXvbqBzQin66Gpn2x1cJ7PFu+6iVxmn8p7Jm6LXBc9WNLyVe7ts4n5w1zi/Cs9YbtMzf7V10bOiYS1ErhlkyPWTmQuT8re+v12tvjnidI7We3oz94xS41M79FPNXyH0qpz1Tb8UDlJ6oxK2l1KflOfq6Opru3JdcwrHOd/f/zmFrYwgm4YhalJC3huL+1enp/mR7raU9eMYYe2G2FhUJTIkt5ySnWsXjzhNVV3LNFCC+zGa44pKlsi8jv7zg6dYiv7jc6dZ+A2zBApQ=
28KCVBqs8Q3yCLu5
